A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients.
Lung Cancer(2020)
摘要
•Tislelizumab + chemotherapy had antitumor activity in patients with advanced lung cancer.•Median PFS were 9.0 (NSQ), 7.0 (SQ-A), and 6.9 months (SCLC); PFS in SQ-B was immature.•Median OS was not reached in all cohorts except for SCLC (15.6 months).•Distinct immune/cell cycle–related gene signatures were associated with efficacy.
更多查看译文
关键词
Tislelizumab,Programmed cell death-1 (PD-1),Immunotherapy,Advanced lung cancer,Gene expression profile
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络